Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-054 | 121-14-2 | 2,4-Dinitrotoluene | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| Yes | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Mice | B6C3F1 | Male | Intraperitoneal Injection | Skin | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| Yes | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Skin | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| Yes | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Skin | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| Yes | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (PAPILLOMA OR CARCINOMA) | Neoplastic Lesions |
| Yes | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (SQUAMOUS CELL CARCINOMA OR BASAL CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-127 | 99-59-2 | 5-Nitro-o-anisidine | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (TRICHOEPITHELIOMA, SEBACEOUS ADENOMA, BASAL CELL CARCINOMA, SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (BASAL CELL ADENOMA, SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| Yes | TR-146 | 139-94-6 | Nithiazide | Rats | F344/N | Female | Dosed-Feed | Skin | Positive | Positive | (FIBROADENOMA OR CYSTADENOMA) | Neoplastic Lesions |
| Yes | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 1/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 5/50 3/50 8/50 | Neoplastic Lesions |
| Yes | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | TRICHOEPITHELIOMA 0/50 0/50 7/50; SEBACEOUS ADENOMA 0/50 0/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 1/50 10/50 | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50 | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50 | Neoplastic Lesions |
| Yes | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 1/50 4/35 26/65 30/50, BASAL CELL CARCINOMA 0/50 1/35 5/65 6/50, COMBINED 1/50 5/35 28/65 32/50; KERATOACANTHOMA 1/50 1/35 4/65 7/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 5/65 5/50, SEBACEOUS GLAND CARCINOMA 1/50 0/35 0/65 1/50, COMBINED 1/50 1/35 5/65 6/50; SQUAMOUS CELL PAPILLOMA 1/50 0/35 3/65 2/50, SQUAMOUS CELL CARCINOMA 0/50 2/35 8/65 7/50, COMBINED 1/50 2/35 11/65 9/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50 | Neoplastic Lesions |
| Yes | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/50 3/35 5/65 3/50, BASAL CELL CARCINOMA 0/50 1/35 2/65 2/50, COMBINED 0/50 4/35 7/65 5/50 | Neoplastic Lesions |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 3/45 5/75 5/60 OR BASAL CELL CARCINOMA 0/60 0/45 5/75 4/60 COMBINED 0/60 3/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA 0/60 1/45 6/75 5/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 4/75 7/60 COMBINED 0/60 3/45 9/75 12/60 | Neoplastic Lesions |
| Yes | TR-407 | 2425-85-6 | C.I. Pigment Red 3 | Rats | F344/N | Male | Dosed-Feed | Skin | Some Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 2/50 6/50 | May Have Been Related |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50 | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50 | Neoplastic Lesions |
| Yes | TR-362 | 106-87-6 | 4-Vinyl-1-cyclohexene diepoxide | Mice | B6C3F1 | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/50 6/50 37/50 43/50 | Neoplastic Lesions |
| Yes | TR-362 | 106-87-6 | 4-Vinyl-1-cyclohexene diepoxide | Mice | B6C3F1 | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/50 14/50 40/50 43/50 | Neoplastic Lesions |
| Yes | TR-362 | 106-87-6 | 4-Vinyl-1-cyclohexene diepoxide | Rats | F344/N | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | BASAL CELL CARCINOMA 2/50 5/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 16/50 34/50 | Neoplastic Lesions |
| Yes | TR-362 | 106-87-6 | 4-Vinyl-1-cyclohexene diepoxide | Rats | F344/N | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | BASAL CELL CARCINOMA 2/50 4/50 8/50; SQUAMOUS CELL CARCINOMA 0/50 33/50 36/50 | Neoplastic Lesions |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 10/45 52/75 29/60 OR BASAL CELL CARCINOMA 0/60 1/45 4/75 2/60 COMBINED 0/60 11/45 54/75 30/60; SEBACEOUS GLAND ADENOMA 0/60 0/45 7/75 5/60; KERATOACANTHOMA 1/60 1/45 8/75 5/60; SQUAMOUS CELL PAPILLOMA 0/60 0/45 8/75 15/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 10/75 13/60 COMBINED 0/60 2/45 17/75 27/60 | Neoplastic Lesions |
| Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60 | Neoplastic Lesions |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50 | Neoplastic Lesions |
| Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 1/48, 4/46, 7/47) | Neoplastic Lesions |
| Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | (SUBCUTANEOUS) FIBROMA 3/60 3/60 18/60 20/60 FIBROMA OR FIBROSARCOMA 3/60 3/60 21/60 22/60 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 2/47, 0/48, 7/48) | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/48 0/46 2/48 | Neoplastic Lesions |
| Yes | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | FIBROMA 1/50 9/50 8/50 5/50 4/50 OR FIBROMA OR FIBROSARCOMA 1/50 12/50 8/50 8/50 4/50 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60 | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/47, 1/48, 5/47, 8/48) | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 2/47 | Neoplastic Lesions |
| Yes | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Male | Inhalation | Skin | Clear Evidence | Equivocal Evidence | FIBROMA 1/50 4/50 7/50 3/50; FIBROMA OR FIBROSARCOMA 2/50 4/50 8/50 4/50 | May Have Been Related |
| Yes | TR-485 | 434-07-1 | Oxymetholone | Rats | F344/N | Female | Gavage | Skin | Clear Evidence | Clear Evidence | COMBINED 0/50 0/50 4/50 5/50 | Neoplastic Lesions |
| Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | (SUBCUTANEOUS) LIPOMA 0/60 4/60 13/60 13/60 10/60 12/60 FIBROMA 5/60 46/60 52/60 59/60 45/60 52/60 FIBROSARCOMA 0/60 7/60 17/60 20/60 8/60 12/60 COMBINED 5/60 47/60 55/60 59/60 47/60 53/60 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | subcutaneous tissue fibroma, fibrosarcoma or sarcoma 1/48 0/48 0/48 1/48 5/48 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma, fibrous histocytoma, myxosarcoma, neurofibrosarcoma, or sarcoma 0/48 0/46 3/48 10/45 6/43 squamous cell carcinoma 0/48 0/46 0/48 0/45 2/43 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma 0/45 1/48 2/47 2/47 9/45 sarcoma 0/45 0/48 1/47 3/47 3/45 fibrosarcoma or sarcoma 0/45 1/48 3/47 5/47 12/45 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 1/48 2/47 1/47 8/46 squamous cell carcinoma 0/47 0/48 0/47 0/47 2/46 squamous cell papilloma or carcinoma 0/47 1/48 2/47 1/47 9/46 | Neoplastic Lesions |
| Yes | TR-590 | 1309-64-4 | Antimony Trioxide | Mice | B6C3F1 | Female | Inhalation | Skin | Clear Evidence | Equivocal Evidence | squamous cell carcinoma (0/50, 0/50, 0/50, 2/50) | May Have Been Related |
| Yes | TR-590 | 1309-64-4 | Antimony Trioxide | Mice | B6C3F1 | Male | Inhalation | Skin | Clear Evidence | Clear Evidence | fibrous histiocytoma (0/50, 1/50, 1/50, 4/50); fibrous histiocytoma or fibrosarcoma (0/50, 1/50, 3/50, 4/50) | Neoplastic Lesions |
| Yes | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Female | Inhalation | Skin | Clear Evidence | Equivocal Evidence | Squamous cell papilloma, keratoacanthoma, basal cell adenoma or carcinoma 1/50 1/50 1/50 4/50 | May Have Been Related |
| Yes | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Male | Inhalation | Skin | Some Evidence | Some Evidence | Keratoacanthoma 0/50 3/50 6/50 6/50 keratoacanthoma or squamous cell carcinoma 1/50 4/50 6/50 8/50 keratoacanthoma, basal cell adenoma or carcinoma or squamous cell carcinoma 1/50 7/50 9/50 10/50 | Neoplastic Lesions |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (subcutaneous tissue): fibroma 4/50 6/50 10/50 15/50 | Neoplastic Lesions |
| Yes | TR-544 | 3252-43-5 | Water disinfection byproducts (Dibromoacetonitrile) | Rats | F344/N | Female | Dosed-Water | Skin | Some Evidence | Equivocal Evidence | Squamous cell papilloma, keratoacanthoma, basal cell adenoma or carcinoma 0/50 0/50 3/50 4/50 | May Have Been Related |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | squamous cell papilloma, keratoacanthoma, sebaceous gland adenoma, basal cell adenoma, basal cell carcinoma, or squamous cell carcinoma 9/50 7/50 15/50 21/50 | Neoplastic Lesions |
| Yes | TR-584 | 700-06-1 | Indole-3-carbinol | Rats | Harlan Sprague-Dawley | Female | Gavage | Skin | Some Evidence | Equivocal Evidence | fibroma 1/50 0/50 0/50 4/50 fibrosarcoma 1/50 0/50 0/50 1/50 fibroma or fibrosarcoma 2/50 0/50 0/50 5/50 | May Have Been Related |
| Yes | TR-569 | 30516-87-1 | AZT + NVP + 3TC | Mice | MV | Male | Gavage | Skin | Some Evidence | Some Evidence | (subcutaneous tissue): fibroma, fibrous, histiocytoma, or fibrosarcoma 2/65 2/47 7/48 12/48 -- AZT/3TC/NVP | Neoplastic Lesions |
| Yes | TR-574 | 87-66-1 | Pyrogallol | Mice | B6C3F1/N | Female | Topical Application | Skin | Some Evidence | Some Evidence | (site of application): squamous cell carcinoma 0/50, 0/50, 0/50, 4/50 | Neoplastic Lesions |
| Yes | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Female | Gavage | Skin | Clear Evidence | Clear Evidence | Fibrosarcoma 1/50 6/50 5/50 8/50 fibrosarcoma or malignant schwannoma 2/50 8/50 7/50 12/50 | Neoplastic Lesions |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Female | Inhalation | Intestines (Large) | Clear Evidence | Clear Evidence | Adenoma 0/50 1/50 2/50 5/50 | Neoplastic Lesions |
| No | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Male | Inhalation | Intestines (Large) | Some Evidence | Some Evidence | Adenoma 0/50 0/50 2/50 1/50 | Neoplastic Lesions |
| No | TR-564 | 106-94-5 | 1-Bromopropane | Mice | B6C3F1/N | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/bronchiolar adenoma 1/50 6/50 4/50 10/50 alveolar/bronchiolar carcinoma 0/50 7/50 5/50 4/50 alveolar/bronchiolar adenoma or carcinoma 1/50 9/50 8/50 14/50 | Neoplastic Lesions |
| No | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Male | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Some Evidence | Equivocal Evidence | Malignant: 0/50 2/50 2/50 4/50 | May Have Been Related |
| No | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Male | Inhalation | Pancreas Islet Cell | Some Evidence | Equivocal Evidence | Adenoma 0/50 5/50 4/50 5/50 | May Have Been Related |
| Yes | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Female | Inhalation | Skin | Clear Evidence | Equivocal Evidence | Squamous cell papilloma, keratoacanthoma, basal cell adenoma or carcinoma 1/50 1/50 1/50 4/50 | May Have Been Related |
| Yes | TR-564 | 106-94-5 | 1-Bromopropane | Rats | F344/N | Male | Inhalation | Skin | Some Evidence | Some Evidence | Keratoacanthoma 0/50 3/50 6/50 6/50 keratoacanthoma or squamous cell carcinoma 1/50 4/50 6/50 8/50 keratoacanthoma, basal cell adenoma or carcinoma or squamous cell carcinoma 1/50 7/50 9/50 10/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/51 0/53 1/51 3/55 1/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 3/50 2/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/52 0/50 1/51 2/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 25/50 45/51 46/53 45/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/51 2/53 4/51 3/53 3/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Seminal Vesicle | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/52 1/50 4/51 11/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Urinary Bladder | Clear Evidence | Clear Evidence | TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Unspecified) | Clear Evidence | Equivocal Evidence | HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Liver | Clear Evidence | Clear Evidence | ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50 | May Have Been Related |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/50 5/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Nasal Cavity | Clear Evidence | Clear Evidence | ADENOMA 0/50 44/50 49/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Nasal Cavity | Clear Evidence | Clear Evidence | ADENOMA 0/50 48/50 48/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50 | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50 | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50 | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50 | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Vascular System (Spleen) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50 | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Preputial Gland | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| Yes | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (SQUAMOUS CELL CARCINOMA OR BASAL CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland C-Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Mice | B6C3F1 | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Mice | B6C3F1 | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | (SEBACEOUS ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | (SQUAMOUS CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-054 | 121-14-2 | 2,4-Dinitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-054 | 121-14-2 | 2,4-Dinitrotoluene | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-054 | 121-14-2 | 2,4-Dinitrotoluene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (FIBROADENOMA) | Neoplastic Lesions |
| Yes | TR-054 | 121-14-2 | 2,4-Dinitrotoluene | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| Yes | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (PAPILLOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 2/44 3/75 1/60 | May Have Been Related |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/60 2/45 14/75 20/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 2/60 1/45 7/75 6/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59 | Neoplastic Lesions |